Noile-Immune Biotech Inc. Logo

Noile-Immune Biotech Inc.

Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.

4893 | T

Overview

Corporate Details

ISIN(s):
JP3759560000
LEI:
Country:
Japan
Address:
港区芝大門二丁目12番10号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Noile-Immune Biotech Inc. is a clinical-stage biotechnology company focused on the development and commercialization of novel cancer immunotherapies. The company specializes in CAR-T cell therapy aimed at treating solid tumors, a significant challenge in oncology. Its core is the proprietary PRIME (Proliferation-Inducing and Migration-Enhancing) technology, a next-generation platform designed to augment the efficacy of CAR-T cells. Noile-Immune advances its therapeutic pipeline through in-house research and strategic partnerships with academic and corporate entities, with the mission to create transformative treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 09:15
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-08-08 09:14
Interim Report
半期報告書-第11期(2025/01/01-2025/12/31)
Japanese 143.9 KB
2025-04-01 09:11
Post-Annual General Meeting Information
臨時報告書
Japanese 23.5 KB
2025-03-28 05:44
Registration Form
確認書
Japanese 8.2 KB
2025-03-28 05:43
Governance Information
内部統制報告書-第10期(2024/01/01-2024/12/31)
Japanese 21.2 KB
2025-03-28 05:42
Annual Report
有価証券報告書-第10期(2024/01/01-2024/12/31)
Japanese 4.1 MB
2024-10-15 05:07
Report Publication Announcement
訂正確認書
Japanese 8.2 KB
2024-10-15 05:06
Interim Report
訂正半期報告書-第10期(2024/01/01-2024/12/31)
Japanese 124.4 KB
2024-08-13 05:02
Interim Report
半期報告書-第10期(2024/01/01-2024/12/31)
Japanese 150.3 KB
2024-08-13 05:00
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-14 10:07
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-14 10:05
Quarterly Report
四半期報告書-第10期第1四半期(2024/01/01-2024/03/31)
Japanese 117.7 KB
2024-04-02 06:49
Post-Annual General Meeting Information
臨時報告書
Japanese 22.2 KB
2024-03-29 06:19
Registration Form
確認書
Japanese 8.2 KB
2024-03-29 06:18
Governance Information
内部統制報告書-第9期(2023/01/01-2023/12/31)
Japanese 21.2 KB

Automate Your Workflow. Get a real-time feed of all Noile-Immune Biotech Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Noile-Immune Biotech Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Noile-Immune Biotech Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.